27 March 2017
News and Views
Links and Services
The latest issue of the Clinical Gastroenterology & Hepatology examines risks of serious infection or lymphoma with anti–tumor necrosis factor therapy for pediatric inflammatory bowel disease.
Many physicians hesitate to recommend anti–tumor necrosis factor (TNF) therapy for pediatric pati
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors